Wysa vs Alan

Alan has a disclosed valuation of $5.8B, while Wysa's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Alan has raised more in total funding at $750M, compared to Wysa's $30M — a gap of $720M. Combined, the two companies have completed 4 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Wysa sits at 63/100. That 20-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Wysa was founded by Jo Aggarwal in 2015. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Wysa: Wysa is an AI mental health platform that provides evidence-based cognitive behavioral therapy techniques through a conversational AI chatbot, offering anonymous, stigma-free mental health support accessible via smartphone at any hour. The platform uses clinically validated CBT, DBT, and mindfulness exercises delivered conversationally, and provides a step-up pathway to licensed human therapists for users requiring more intensive support.\n\nThe company raised approximately $30M in Series B funding and has deployed its platform to over five million users globally, including through enterprise employee wellness programs, NHS partnerships in the UK, and healthcare system integrations in the United States and India. Wysa has published peer-reviewed clinical evidence demonstrating statistically significant improvements in depression and anxiety scores.\n\nMental health care access is a global crisis with a severe therapist shortage that AI can meaningfully address at the first-line support level. Wysa's combination of clinical validation, enterprise and payer relationships, and scalable AI delivery model positions it as one of the more credible players in the crowded digital mental health space. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Wysa got there first, launching in 2015 — that's 1 year of extra runway. Alan didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Wysa has about 50-200 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Wysa and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.